CA2532925A1 - Azolo triazines and pyrimidines - Google Patents

Azolo triazines and pyrimidines Download PDF

Info

Publication number
CA2532925A1
CA2532925A1 CA002532925A CA2532925A CA2532925A1 CA 2532925 A1 CA2532925 A1 CA 2532925A1 CA 002532925 A CA002532925 A CA 002532925A CA 2532925 A CA2532925 A CA 2532925A CA 2532925 A1 CA2532925 A1 CA 2532925A1
Authority
CA
Canada
Prior art keywords
pyrimidines
formula
see formula
azolo
triazines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002532925A
Other languages
French (fr)
Other versions
CA2532925C (en
Inventor
Liqi He
Paul Joseph Gilligan
Argyrios Georgios Arvanitis
Robert John Chorvat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol-Myers Squibb Pharma Company
Liqi He
Paul Joseph Gilligan
Argyrios Georgios Arvanitis
Robert John Chorvat
The Du Pont Merck Pharmaceutical Company
Du Pont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Company, Liqi He, Paul Joseph Gilligan, Argyrios Georgios Arvanitis, Robert John Chorvat, The Du Pont Merck Pharmaceutical Company, Du Pont Pharmaceuticals Company filed Critical Bristol-Myers Squibb Pharma Company
Priority claimed from US08/899,242 external-priority patent/US6124289A/en
Priority claimed from CA002259583A external-priority patent/CA2259583C/en
Publication of CA2532925A1 publication Critical patent/CA2532925A1/en
Application granted granted Critical
Publication of CA2532925C publication Critical patent/CA2532925C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

Corticotropin releasing factor (CRF) antagonists of formula I or II: (see formula I) (see formula II) wherein A is CR, and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
CA002532925A 1996-07-24 1997-07-23 Azolo triazines and pyrimidines Expired - Lifetime CA2532925C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68604796A 1996-07-24 1996-07-24
US2329096P 1996-07-24 1996-07-24
US60/023,290 1996-07-24
US60/686,047 1996-07-24
US08/899,242 1997-07-23
US08/899,242 US6124289A (en) 1996-07-24 1997-07-23 Azolo triazines and pyrimidines
CA002259583A CA2259583C (en) 1996-07-24 1997-07-23 Azolo triazines and pyrimidines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002259583A Division CA2259583C (en) 1996-07-24 1997-07-23 Azolo triazines and pyrimidines

Publications (2)

Publication Number Publication Date
CA2532925A1 true CA2532925A1 (en) 1998-01-29
CA2532925C CA2532925C (en) 2009-10-20

Family

ID=36141771

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002532925A Expired - Lifetime CA2532925C (en) 1996-07-24 1997-07-23 Azolo triazines and pyrimidines

Country Status (1)

Country Link
CA (1) CA2532925C (en)

Also Published As

Publication number Publication date
CA2532925C (en) 2009-10-20

Similar Documents

Publication Publication Date Title
IL137019A0 (en) Azolo triazines and pyrimidines
LV12292A (en) Triazine and pyrimidine azole derivatives
MY132871A (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
GR3029561T3 (en) Pyrrolopyrimidines as crf antagonists.
AU3131697A (en) Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
AU2222500A (en) 1h-imidazo(4,5-d)pyridazin-7-ones, 3h-imidazo(4,5-c)pyridin-4-ones and corresponding thiones as corticotropin releasing factor (crf) receptor ligands
AU4270297A (en) Pyrazinones and triazinones and their derivatives thereof
MY115300A (en) Pyrazolopyrimidines.
WO1997035539A3 (en) Arylamino fused pyridines and pyrimidines
WO2002004453A3 (en) PYRROLO[3,4-d]PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
MY131382A (en) Pyrazoles and pyrazolopyrimidines
MY146935A (en) 4-(2-BUTYLAMINO-2, 7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-yl) PYRAZOLO-[1,5-a]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS
IL134748A0 (en) Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
IE873339L (en) 6-Benzoxazinyl- and¹6-benzothiazinyl-2,3,4,5-tetrahydropyridazin -3-ones.
EP0272914A3 (en) 6-benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones
CA2532925A1 (en) Azolo triazines and pyrimidines
MY141511A (en) Azolo triazines and pyrimidines
MY141976A (en) Azolo triazines and pyrimidines
MY141752A (en) Pyrazolotriazines as crf antagonists
Kagan Psychogenic Forms of School Deadaptation
EP0343832A3 (en) 5h-pyrazolo(4,3-a)quinolizin-5-one compounds exhibiting therapeutic activities
IL103440A0 (en) Heterocyclic compounds and their preparation and use
Manelis et al. Neuropsychological model of brain organization of higher psychic functions in children suffering bronchial asthma
WO2000021978A3 (en) Laminin 5, 13 and 14 and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170724